Detalhe da pesquisa
1.
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385273
2.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
3.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
4.
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Br J Haematol
; 195(3): 405-412, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34500492
5.
Therapeutic strategies for durable response in plasma cell granulomas in the central nervous system.
Ann Hematol
; 98(4): 1027-1029, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30178192
6.
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.
Am J Hematol
; 94(8): E216-E219, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31120638
7.
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
Am J Hematol
; 94(10): E273-E275, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31342556
8.
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience.
Cancers (Basel)
; 16(11)2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38893268
9.
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.
Blood Rev
; 66: 101218, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38852017
10.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Blood Adv
; 8(1): 251-259, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855718
11.
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Transplant Cell Ther
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38834151
12.
Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
Br J Ophthalmol
; 107(7): 901-905, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35144919
13.
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
J Clin Oncol
; 41(11): 2087-2097, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623248
14.
Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.
Transplant Proc
; 55(1): 214-224, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635141
15.
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.
Clin Lymphoma Myeloma Leuk
; 23(10): 757-763, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453865
16.
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Leuk Lymphoma
; 63(6): 1339-1347, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045791
17.
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Leuk Res Rep
; 18: 100358, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36353199
18.
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Neuro Oncol
; 23(1): 112-121, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32750704
19.
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.
Expert Rev Hematol
; 13(6): 669-686, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32290719
20.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Blood Cancer J
; 14(1): 63, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609386